(Q37960073)

25 August 2017

title

Approaches to the pharmacological treatment of obesity (English)

1 reference

25 August 2017

0 references

1 reference

1

Victoria Salem

1 reference

25 August 2017

Stephen R Bloom

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Expert Review of Clinical Pharmacology

25 August 2017

published in

1 reference

25 August 2017

volume

3

1 reference

25 August 2017

issue

1

1 reference

25 August 2017

page(s)

73-88

1 reference

A potential decline in life expectancy in the United States in the 21st century

25 August 2017

cites work

1 reference

Central obesity and multivariable cardiovascular risk as assessed by the Framingham prediction scores.

21 January 2018

1 reference

Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.

21 January 2018

1 reference

The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat.

21 January 2018

1 reference

Impact of overweight on the risk of developing common chronic diseases during a 10-year period

21 January 2018

1 reference

Cancer incidence and mortality after gastric bypass surgery

21 January 2018

1 reference

Gastric banding for the treatment of type 2 diabetes mellitus in morbidly obese.

21 January 2018

1 reference

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

21 January 2018

1 reference

Long-term mortality after gastric bypass surgery

21 January 2018

1 reference

Leptin and insulin action in the central nervous system

21 January 2018

1 reference

Factors promoting and ameliorating the development of obesity

21 January 2018

1 reference

The role of gastrointestinal vagal afferents in the control of food intake: current prospects

21 January 2018

1 reference

Minireview: human obesity-lessons from monogenic disorders

21 January 2018

1 reference

Variation in FTO contributes to childhood obesity and severe adult obesity

21 January 2018

1 reference

The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase

21 January 2018

1 reference

Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet

21 January 2018

1 reference

A self-regulation program for maintenance of weight loss

21 January 2018

1 reference

Weight regain in U.S. adults who experienced substantial weight loss, 1999-2002.

21 January 2018

1 reference

Safety of drug therapies used for weight loss and treatment of obesity

21 January 2018

1 reference

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

The anorexic agents, sibutramine and fenfluramine, depress GABA(B)-induced inhibitory postsynaptic potentials in rat mesencephalic dopaminergic cells

21 January 2018

1 reference

Explanations for weight loss after ileojejunal bypass in gross obesity

21 January 2018

1 reference

Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass

21 January 2018

1 reference

Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety.

21 January 2018

1 reference

Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters

21 January 2018

1 reference

Antiobesity surgery in Sweden from 1980 to 2005: a population-based study with a focus on mortality

21 January 2018

1 reference

Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers

21 January 2018

1 reference

Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors

21 January 2018

1 reference

A small molecule that blocks fat synthesis by inhibiting the activation of SREBP.

21 January 2018

1 reference

Minireview: Endocannabinoids and their receptors as targets for obesity therapy

21 January 2018

1 reference

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

21 January 2018

1 reference

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization

21 January 2018

1 reference

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity

21 January 2018

1 reference

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

21 January 2018

1 reference

Naltrexone for the treatment of obesity: review and update

21 January 2018

1 reference

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women

21 January 2018

1 reference

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects

21 January 2018

1 reference

Effects of the obese gene product on body weight regulation in ob/ob mice

21 January 2018

1 reference

Weight-reducing effects of the plasma protein encoded by the obese gene

21 January 2018

1 reference

Physiological response to long-term peripheral and central leptin infusion in lean and obese mice

21 January 2018

1 reference

Identification and expression cloning of a leptin receptor, OB-R

21 January 2018

1 reference

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

21 January 2018

1 reference

Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial

21 January 2018

1 reference

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

21 January 2018

1 reference

Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice

21 January 2018

1 reference

Identification of SOCS-3 as a potential mediator of central leptin resistance

21 January 2018

1 reference

Gut hormone PYY(3-36) physiologically inhibits food intake

21 January 2018

1 reference

Inhibition of food intake in obese subjects by peptide YY3-36

21 January 2018

1 reference

Attenuated peptide YY release in obese subjects is associated with reduced satiety.

21 January 2018

1 reference

Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans

21 January 2018

1 reference

Critical role for peptide YY in protein-mediated satiation and body-weight regulation

21 January 2018

1 reference

Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse.

21 January 2018

1 reference

The satiety hormone peptide YY as a regulator of appetite.

21 January 2018

1 reference

The NPY system in stress, anxiety and depression

21 January 2018

1 reference

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults

21 January 2018

1 reference

Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome

21 January 2018

1 reference

Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice.

21 January 2018

1 reference

Characterization of the effects of pancreatic polypeptide in the regulation of energy balance

21 January 2018

1 reference

Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice

21 January 2018

1 reference

Pancreatic polypeptide reduces appetite and food intake in humans

21 January 2018

1 reference

Distribution of peripherally injected peptide YY ([125I] PYY (3-36)) and pancreatic polypeptide ([125I] hPP) in the CNS: enrichment in the area postrema.

21 January 2018

1 reference

Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans.

21 January 2018

1 reference

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study

21 January 2018

1 reference

Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats

21 January 2018

1 reference

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

21 January 2018

1 reference

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects.

21 January 2018

1 reference

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure

21 January 2018

1 reference

The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway

21 January 2018

1 reference

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

21 January 2018

1 reference

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

21 January 2018

1 reference

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide

21 January 2018

1 reference

Peripheral oxyntomodulin reduces food intake and body weight gain in rats.

21 January 2018

1 reference

Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial

21 January 2018

1 reference

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

21 January 2018

1 reference

Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging

21 January 2018

1 reference

C-Terminal octapeptide of cholecystokinin decreases food intake in obese men☆☆☆

21 January 2018

1 reference

Satiety effects of a physiological dose of cholecystokinin in humans

21 January 2018

1 reference

Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone

21 January 2018

1 reference

A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans

21 January 2018

1 reference

Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues

21 January 2018

1 reference

Circulating ghrelin levels are decreased in human obesity.

21 January 2018

1 reference

Ghrelin causes hyperphagia and obesity in rats.

21 January 2018

1 reference

Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats

21 January 2018

1 reference

Ghrelin stimulates GH but not food intake in arcuate nucleus ablated rats

21 January 2018

1 reference

Vagotomy dissociates short- and long-term controls of circulating ghrelin

21 January 2018

1 reference

Ghrelin modulates brain activity in areas that control appetitive behavior

21 January 2018

1 reference

Antagonism of ghrelin receptor reduces food intake and body weight gain in mice

21 January 2018

1 reference

Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats

21 January 2018

1 reference

A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain

21 January 2018

1 reference

Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats

21 January 2018

1 reference

Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice

21 January 2018

1 reference

Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides.

21 January 2018

1 reference

PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans

21 January 2018

1 reference

Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y

21 January 2018

1 reference

Rapid development of tolerance to the behavioural actions of cholecystokinin

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECP.09.54

1 reference

25 August 2017

1 reference